PGXL Laboratories provides pharmacogenetic testing and interpretive services.
It has developed CYP2C9/VKORC1 tests for accurate anticoagulant dosing.
Along with its clinical practice, PGXL performs contract research for manufacturers of pharmaceuticals and medical equipment.
PGXL Laboratories executive vice-president and co-founder Mark Linder said with their comprehensive menu of molecular applications in the pharmacogenetics arena, they have found AutoGenomics to be a very suitable partner in meeting their emerging testing needs.
AutoGenomics senior vice president Ramanath Vairavan said the versatility of BioFilmChip Microarray technology allows to rapidly develop new test applications to meet the evolving needs in companion diagnostic testing and enable PGXL Labs to expand the array of personalized medicine tests.